Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa proof-of-concept study of subcutaneous folate-based liposomal methotrexate in active rheumatoid arthritis
2023-510258-17-00Phase 2Completed
- Sponsor
- Solfarcos
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in rheumatoid arthritis (RA), sponsored by Solfarcos. Primary endpoints: Change from baseline in DAS28-CRP at Week 14, Change from baseline in DAS28-CRP at Weeks 4, 8, and 12 and 9 more. Started May 2024; status: completed.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2023-510258-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510258-17-00.